论文部分内容阅读
目的研究SRY box containing gene 30(SOX30)基因在前列腺癌组织中表达情况,并且分析SOX30的表达与前列腺癌临床病理特征之间的相关性;并检测SOX30在前列腺癌细胞PC3、DU145、LNCaP以及正常人前列腺上皮细胞RWPE-1中的表达情况。方法采用免疫组织化学方法检测SOX30在前列腺癌组织中表达特点,采用逆转录实时定量聚合酶链式反应(RT-qPCR)和蛋白印迹法(Western Blotting)分析SOX30在PC3、DU145、LNCaP以及正常人前列腺上皮细胞RWPE-1中的表达情况,运用统计学方法分析SOX30蛋白表达量与前列腺癌临床病理特征之间的关系。结果在123例前列腺癌中,68例(55.28%)发生SOX30表达缺失,并且SOX30表达缺失与前列腺分期(P=0.001)、Gleason评分(P<0.001)有明显的相关性;与正常人前列腺上皮细胞RWPE-1相比,SOX30在PC3、DU145、LNCaP中表达明显降低。结论 SOX30可能是作为一个肿瘤抑制基因在前列腺癌的发生发展中起着重要作用。
Objective To investigate the expression of SRX box containing gene 30 (SOX30) in prostate cancer tissues and to analyze the correlation between the expression of SOX30 and the clinicopathological features of prostate cancer. To detect the expression of SOX30 in prostate cancer cells PC3, DU145, LNCaP and normal Expression of human prostate epithelial cells in RWPE-1. Methods The expression of SOX30 was detected by immunohistochemistry in prostate cancer tissues. The expression of SOX30 in PC3, DU145, LNCaP and normal human was analyzed by RT-qPCR and Western Blotting. Prostate epithelial cells RWPE-1 expression, the use of statistical methods to analyze the expression of SOX30 protein and the relationship between the clinicopathological features of prostate cancer. Results In 123 cases of prostate cancer, 68 cases (55.28%) had SOX30 expression loss, and the absence of SOX30 expression was significantly correlated with prostate staging (P = 0.001) and Gleason score (P <0.001) SOX30 was significantly decreased in PC3, DU145 and LNCaP cells compared with RWPE-1 cells. Conclusion SOX30 may play an important role in the development of prostate cancer as a tumor suppressor gene.